Oxford Immunotec Global plc is a global, high-growth diagnostics company focused on developing and commercialising proprietary tests for the management of immune-regulated conditions.
The company has an extensive presence in the USA, and since November 2013 has been listed on NASDAQ. Revenues for the year ended 31 December 2015 were $62.8 million an increase of 33% on a constant currency basis compared to prior year.
Oxford Immunotec’s first product is the T-SPOT®TB test, which is used to test for tuberculosis infection. This diagnostic test has been approved for sale in over 50 countries, including the USA—where it has received pre-market approval from the FDA—Europe—where it has obtained a CE mark—Japan, and China. The T-SPOT®TB test has advantages over current TB diagnosis methods (such as the tuberculin skin test), as it returns results with greater accuracy and speed, and is suitable for use in a wider range of patients.
The company’s portfolio has two other products, the T-SPOT.CMV test and the T-SPOT.PRT test as part of a series of products intended for the transplantation market. Oxford Immunotec also has six active development programmes, each of which leverages its T cell, B cell and innate immune measuring technology.